Whitepaper - Where Speed Meets Complexity In Bioprocess Development

Bioprocessing today operates on two distinct tracks. For traditional monoclonal antibodies, the field has largely been platformized, meaning the primary pressure is now speed — compressing gene-to-IND timelines from a year to as little as six months. For complex modalities like bispecifics and gene therapies, however, significant technical complexity remains, and the underlying technologies are not always mature enough to meet the standards set by mAb development.

Process intensification, primarily a mAb-focused strategy, offers real benefits: higher titers, smaller manufacturing footprints, and greater agility. But these gains come with tradeoffs. Tighter operating windows demand real-time data and feedback, and companies that run fed-batch processes in early clinical phases before switching to intensified approaches in later phases face difficult comparability questions. Introducing intensification earlier in development could mitigate this risk, but it requires combining deep product and process knowledge into an accessible, operationalized service.

Scale-up presents its own challenges. Processes designed at bench scale do not always translate effectively to GMP manufacturing — high media volumes may be impractical at full scale, and equipment available in development settings may not exist or perform the same way at commercial scale. Success ultimately depends on designing with manufacturing in mind from the very beginning, supported by well-trained teams and robust data interpretation capabilities.